P2Y12 Receptor Antagonist, Clopidogrel, Does Not Contribute to Risk of Osteoporotic Fractures in Stroke Patients
Background: Stroke is a leading cause of mortality and morbidity. It is associated with excessive bone loss and risk of fracture in stroke patients is high. The P2Y12R antagonist and platelet inhibitor, clopidogrel, is widely used for secondary prevention after a stroke. However, recent studies have...
Main Authors: | Niklas R. Jørgensen, Peter Schwarz, Helle K. Iversen, Peter Vestergaard |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2017-11-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/article/10.3389/fphar.2017.00821/full |
Similar Items
-
Role of clopidogrel role in secondary prevention of ischemic stroke
by: K. S. Meshkova, et al.
Published: (2014-12-01) -
A Combination of Aspirin and Clopidogrel Predict More Favorable Dynamics of Platelet Reactivity versus Clopidogrel Alone in the Acute Phase of Minor Stroke
by: Adam Wiśniewski, et al.
Published: (2021-05-01) -
Identification and Functional Characterization of a Novel Mutation in the Human Calcium-Sensing Receptor That Co-Segregates With Autosomal-Dominant Hypocalcemia
by: Anne Qvist Rasmussen, et al.
Published: (2018-04-01) -
Aspirin and clopidogrel resistance in Indian patients with ischemic stroke and its associations with gene polymorphisms: A pilot study
by: Samir Patel, et al.
Published: (2019-01-01) -
The Phenomenon of Clopidogrel High On-Treatment Platelet Reactivity in Ischemic Stroke Subjects: A Comprehensive Review
by: Adam Wiśniewski, et al.
Published: (2020-09-01)